Gamma hydroxybutyrate, known as GHB, is a central nervous system depressant with a short list of legitimate medical uses and a longer history as a club drug and a substance associated with drug facilitated sexual assault. Employers, clinics, and parents asking whether GHB shows up on a drug test usually get an unsatisfying answer: not on the panel you already run. GHB is not one of the drugs included in a standard workplace or at home multi panel screen, and testing for it specifically brings challenges that most other drugs do not, starting with the fact that the body produces a small amount of GHB on its own.
This article explains what GHB is, why it is left off standard panels, how laboratories distinguish drug use from the body's own baseline levels, and what the legal status of GHB and the prescription medication sodium oxybate means for testing and documentation. It does not cover how to avoid or beat a test. Everything here is written from the detection and laboratory side.
What GHB is and where it comes from
According to the Drug Enforcement Administration, gamma hydroxybutyric acid is chemically known as 4 hydroxybutanoic acid. It occurs naturally in the central nervous system in very small concentrations as a byproduct of the neurotransmitter GABA, and it can also act as a neurotransmitter or neuromodulator in its own right. Outside the body, GHB is produced illegally and sold as a powder or a clear, slightly salty tasting liquid, most often associated with dance clubs and party settings. The DEA's fact sheet notes that GHB analogues such as gamma butyrolactone (GBL) and 1,4 butanediol (BD) are frequently sold as substitutes because they convert to GHB after ingestion, producing similar effects. See the DEA Drug and Chemical Evaluation Section fact sheet on gamma hydroxybutyric acid for the full profile, including reported case data from poison control centers.
GHB also has a legitimate medical use. The approved by the FDA sodium oxybate, marketed as Xyrem, as a treatment to reduce cataplexy episodes and improve daytime sleepiness in people with narcolepsy. The prescribing information, current as of this writing, is available through the National Library of Medicine's DailyMed label for sodium oxybate oral solution, which lists the controlled substance schedule, dosing structure, and the risk management program required for distribution.
Why GHB is not on a standard drug test panel
Standard workplace drug testing programs, including the federal model that guides most 5 panel and expanded panel immunoassay screens, are built around a defined list of substances such as amphetamines, cannabinoids, cocaine, opiates, and phencyclidine, with many employer programs adding benzodiazepines, barbiturates, or opioids. GHB is not part of that standard list. The Substance Abuse and Mental Health Services Administration, which maintains the federal workplace drug testing program guidance and Mandatory Guidelines, does not include GHB among the substances covered by routine immunoassay screening. An employer or clinic that wants to screen for GHB has to order a specific test for it, typically sent to a laboratory rather than run on an instant cup or dip card.
This matters for two reasons. First, a negative result on a standard multi panel test, including the panels commonly used for pre employment and random workplace programs such as those in American Screening's drug test cup collection, says nothing about GHB one way or the other, because the panel was never designed to look for it. Second, because GHB clears the body quickly, ordering a specific GHB test after the fact, once suspicion arises, can still miss recent use if too much time has passed.
Why GHB is difficult to detect once you do test for it
Two features of GHB make specific testing harder than testing for most other controlled substances: the body's own natural production of GHB, and how fast the drug is metabolized and eliminated.
According to StatPearls, an NIH National Library of Medicine clinical reference, GHB reaches peak plasma concentration between 30 and 60 minutes after ingestion, and its elimination half life ranges from about 20 to 60 minutes. That is fast even compared to other depressants. The same reference notes that GHB toxicity is largely a clinical diagnosis in the emergency setting, because "blood or urine testing for GHB is not routinely available in the hospital setting" and diagnostic confirmation requires gas chromatography and mass spectrometry (GC-MS), a laboratory method rather than a rapid test. See the NCBI Bookshelf StatPearls chapter on gamma hydroxybutyrate toxicity for the clinical detail.
Because GHB is present naturally, a lab cannot simply report "GHB detected" the way it might for a drug the body never makes on its own. A peer reviewed study on urinary GHB published through the National Library of Medicine's PubMed Central archive describes a detection window for GHB in urine of roughly half a day under typical forensic cutoffs, shorter than that in blood, and explains that researchers have looked at novel GHB metabolites and conjugates as a way to extend the reliable detection window beyond what a standard GHB assay allows. Read the study, Urinary concentrations of GHB and its novel amino acid and carnitine conjugates following controlled GHB administration to humans, for the underlying data and cutoff discussion. In practical terms, the takeaway for employers and testing programs is that a GHB test ordered even a day or so after suspected use may already return a negative result, independent of whether use actually occurred.
How labs separate normal body levels from use
Because GHB is endogenous, forensic and clinical laboratories rely on defined cutoff concentrations rather than a simple presence or absence result. A specimen has to test above an established threshold before it is reported as consistent with GHB use rather than the body's own background level. Confirmation is done by GC-MS, which identifies and quantifies GHB precisely, distinguishing it from the small amount everyone has in their system. This is also why a rapid, point of collection GHB test is not generally available the way it is for THC or opiates. Any GHB result that matters for employment, legal, or medical review purposes should go through laboratory confirmation and a documented cutoff, the same standard already used for any non negative result on a standard panel that a lab confirms before it is reported. For background on what that confirmation step looks like more broadly, see American Screening's explainer on what lab confirmation does after a non negative screen.
| Test type | Typical specimen | Covers GHB directly | Method |
|---|---|---|---|
| Standard 5 panel or expanded multi panel cup or dip card | Urine | No, GHB is not part of the standard drug list | Immunoassay |
| Standard oral fluid panel | Oral fluid | No | Immunoassay |
| Specific GHB send out test | Urine or blood | Yes, when specifically ordered | GC-MS with a defined cutoff to separate endogenous levels from use |
| Clinical toxicology evaluation | Clinical judgment, supportive labs | Indirect, GHB toxicity is often a clinical diagnosis | History, symptoms, and exclusion of other causes |
Schedule I versus Schedule III, and why both apply
GHB's legal status is split, and the split matters for how testing and documentation should be handled. Per the DEA fact sheet, GHB itself is controlled in Schedule I under the Controlled Substances Act, while sodium oxybate (Xyrem) is controlled in Schedule III, though the DEA fact sheet notes that Xyrem trafficking outside the prescription system is still subject to Schedule I penalties. In practice this means a person taking sodium oxybate under a valid prescription for narcolepsy is using a Schedule III medication with FDA labeling and a restricted distribution program, while GHB obtained outside that system is treated as a Schedule I controlled substance with no accepted medical use.
For employment testing, this is the same situation programs already handle for other prescribed controlled substances. Any confirmed non negative result should go through a medical review officer, who can review prescription documentation before a result is reported as verified. Because sodium oxybate has significant sedating effects and a REMS (risk evaluation and mitigation strategy) program attached to its distribution, employers in safety sensitive roles may want to build MRO review of GHB related results into the same process already used for other controlled substance prescriptions, rather than treating it as an exception.
The drug facilitated assault context, handled from the testing side
GHB is frequently discussed in connection with drug facilitated sexual assault because of its sedating and amnestic effects and because it can be difficult to taste in a drink. That context is one reason victim advocates and forensic labs have pushed for research into extending the detection window, since a specimen collected any meaningful amount of time after an incident may already fall below the cutoff needed to confirm exposure, as the PubMed Central study above discusses. This is a laboratory and evidentiary limitation, not a reason to delay reporting or testing when GHB exposure is suspected. American Screening's overview of how date rape drug tests work covers the broader category of substances involved and how specimen collection and lab confirmation fit together.
What this means for employers and testing programs
Because GHB is not part of a standard panel, employers should treat it as an add on rather than something already covered. A few practical points:
- Standard cups, dip cards, and oral fluid panels, including multi panel products built around the federal five and common workplace additions, do not screen for GHB. Adding GHB coverage requires a specific test ordered through a laboratory.
- Because of the short detection window, GHB testing generally makes sense as part of a for cause or post incident protocol initiated as soon as possible after a suspected event, rather than as a routine random panel addition, given how quickly the compound clears.
- Any positive or non negative GHB result should be confirmed by GC-MS against an established cutoff and reviewed by a medical review officer before any employment action, the same standard applied to other controlled substance findings.
- State laws on controlled substances, workplace testing, and how confirmed results may be used vary, so employers should confirm requirements with counsel or their testing program administrator rather than assume one national standard applies.
Frequently asked questions
Does GHB show up on a standard 5 panel or 10 panel drug test?
No. GHB is not one of the substances included in standard immunoassay drug test panels used for workplace or at home testing. A standard panel result gives no information about GHB either way.
What kind of test can detect GHB?
A specific GHB test, generally sent to a laboratory and confirmed by gas chromatography and mass spectrometry, can detect GHB in urine or blood. This is a separate order from a standard multi panel drug screen.
How long does GHB stay in urine?
Because GHB is metabolized and eliminated quickly, published research describes a urine detection window of roughly half a day under typical forensic cutoffs, with blood windows generally shorter. Actual detection can vary by dose, individual metabolism, and the cutoff a laboratory uses.
Can a drug test confuse the body's natural GHB with drug use?
GHB is naturally present in the body in very small amounts, so laboratories use defined cutoff concentrations, verified by GC-MS, to distinguish typical background levels from levels consistent with GHB use or exposure.
Is the prescription medication sodium oxybate the same thing as illicit GHB?
They are chemically related, but sodium oxybate, marketed as Xyrem, is a prescription medication carrying FDA approval for narcolepsy, controlled in Schedule III with a restricted distribution program. Non prescription GHB is controlled in Schedule I. A confirmed GHB result in someone with a valid prescription should be reviewed by a medical review officer against that documentation.
Should employers add GHB testing to their drug testing program?
That depends on the industry, role, and risk profile, and employers should generally consult their testing program administrator or counsel. Because GHB is not on standard panels, any employer that wants coverage needs to add a specific laboratory test rather than assume an existing panel already includes it.
This article is for general informational purposes only and is not legal or medical advice. Drug testing requirements and controlled substance laws vary by state and jurisdiction; consult qualified counsel or a medical review officer for guidance specific to your program.
